---
title: "Fosun Pharma Subsidiary Wins China Approval for Norepinephrine Injection"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273376354.md"
description: "Shanghai Fosun Pharmaceutical's subsidiary, Jinzhou Avanc Pharmaceutical, has received approval from China's National Medical Products Administration for Norepinephrine Bitartrate Injection. This drug is intended for restoring blood pressure in acute hypotensive states and maintaining blood pressure after resuscitation, enhancing Fosun's critical-care treatment portfolio in China's hospital market. The stock (HK:2196) currently holds a Hold rating with a price target of HK$22.00 and a market cap of HK$76.32B."
datetime: "2026-01-22T12:37:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273376354.md)
  - [en](https://longbridge.com/en/news/273376354.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273376354.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273376354.md) | [繁體中文](https://longbridge.com/zh-HK/news/273376354.md)


# Fosun Pharma Subsidiary Wins China Approval for Norepinephrine Injection

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.

Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has received approval from China’s National Medical Products Administration for the drug registration of Norepinephrine Bitartrate Injection, a chemical Category 3 product. The injection is approved for restoring blood pressure in acute hypotensive states, as adjunctive therapy in cardiac arrest and for maintaining blood pressure after resuscitation, and as an adjunct to volume replacement in hypovolemic shock to temporarily preserve cerebral and coronary perfusion, expanding the group’s critical-care treatment portfolio and reinforcing its position in China’s hospital and emergency drug market.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

**More about Shanghai Fosun Pharmaceutical (Group) Co**

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a major Chinese healthcare and pharmaceutical group involved in the research, development, manufacturing and distribution of medicines and medical products, with operations spanning both domestic and overseas markets through a portfolio of subsidiaries.

**Average Trading Volume:** 4,345,465

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$76.32B

For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.

### 相关股票

- [FOSUN PHARMA (600196.CN)](https://longbridge.com/zh-CN/quote/600196.CN.md)
- [FOSUN PHARMA (02196.HK)](https://longbridge.com/zh-CN/quote/02196.HK.md)

## 相关资讯与研究

- [Fosun Pharma Subsidiary Wins Approval for Sodium Thiosulfate Antidote Injection](https://longbridge.com/zh-CN/news/279932319.md)
- [Shanghai Fosun Pharmaceutical posts FY net income attributable RMB 3,371 million](https://longbridge.com/zh-CN/news/280390638.md)
- [Yunnan Baiyao Gets Nod to Trial INB301 Injection](https://longbridge.com/zh-CN/news/281464510.md)
- [Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials](https://longbridge.com/zh-CN/news/280731966.md)
- [Huadong Medicine's Unit Gets Nod for HDM2024 for Injection's Clinical Trial](https://longbridge.com/zh-CN/news/280745131.md)